Heterozygote advantage of the MTHFR gene in patients with neural-tube defect and their relatives

Lancet

Volumn 351, Issue 9115, 1998, Pages 1554-1555

  Weitkamp, L R ^a   Tackels, D C ^b   Hunter, A G W ^b   Holmes, L B ^b   Schwartz, C E ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTICLE; DISEASE TRANSMISSION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURAL TUBE DEFECT; PRIORITY JOURNAL; SEX DIFFERENCE; SPONTANEOUS ABORTION;

EID: 0032560374     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61119-1     Document Type: Article

References (4)

1. 1 van der Put NMJ, Eskes TKAB, Blom HJ. Is the common 677®T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? Q J Med 1997; 90: 111-15.
2. 2 Papapetrou C, Lynch SA, Burn J, Edwards YH. Methylenetetrahydrofolate reductase and neural tube defects. Lancet 1996; 348: 58.
3. 3 Ou CY, Stevenson RE, Brown VK, et al 5,10 methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996; 63: 610-14.
4. 4 Elwood JM, Little J, Elwood JH, eds. Epidemiology and control of neural tube defects. Oxford: Oxford University Press, 1992.